|
|
Blood, 1 October 2007, Vol. 110, No. 7, pp. 2309-2315.
Prepublished online as a Blood First Edition Paper on May 11, 2007; DOI 10.1182/blood-2007-02-073528.
 Previous Article | Table of Contents | Next Article 
CLINICAL TRIALS AND OBSERVATIONS
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study
Oliver Ottmann1,
Hervé Dombret2,
Giovanni Martinelli3,
Bengt Simonsson4,
Francois Guilhot5,
Richard A. Larson6,
Giovanna Rege-Cambrin7,
Jerald Radich8,
Andreas Hochhaus9,
Anne Marie Apanovitch10,
Ashwin Gollerkeri11, and
Steven Coutre12
1 Medizinische Klinik II, Johann Wolfgang Goethe Universität, Frankfurt, Germany;
2 Hospital Saint Louis, Paris Cedex, France;
3 Istituto di Ematologica E Oncologica Medica, Policlinico S Orsola, Bologna, Italy;
4 Department of Hematology, University Hospital, Uppsala, Sweden;
5 Clinical Research Centre, Centre Hospitalier Universitaire la Milétrie, Poitiers, France;
6 University of Chicago, IL;
7 Dipartimento di Medicina Interna ii ed Ematologia, Azienda Ospedaliera S. Luigi, Orbassano, Italy;
8 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;
9 Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Germany;
10 Bristol-Myers Squibb, Hopewell, NJ;
11 Bristol-Myers Squibb, Wallingford, CT; and
12 Stanford University School of Medicine, CA
Patients with Philadelphia (Ph) chromosome–positive acute lymphoblastic leukemia (ALL) have a rapid disease course and a poor prognosis. Dasatinib, a novel, oral, multitargeted kinase inhibitor of BCR-ABL and SRC family kinases, has previously induced responses in patients with imatinib-resistant or -intolerant Ph-positive ALL. We present the interim results of a phase 2 study designed to further assess the efficacy, safety, and tolerability of dasatinib 140 mg in this patient population (n = 36). With a minimum follow-up of 8 months, treatment with dasatinib resulted in substantial hematologic and cytogenetic response rates. Major hematologic responses were achieved in 42% (15/36) of patients, 67% of whom remained progression-free. Complete cytogenetic responses were attained by 58% (21/36) of patients. The presence of BCR-ABL mutations conferring imatinib resistance did not preclude a response to dasatinib. Dasatinib was also tolerable, with 6% (2/36) of patients discontinuing therapy as a result of study-drug toxicity. Most adverse events (AEs) were grade 1 or 2; febrile neutropenia was the most frequent severe AE, but this and other cytopenias were manageable with dose reduction. Dasatinib represents a safe and effective treatment option and an important therapeutic advance for patients with Ph-positive ALL. This trial was registered at www.clinicaltrials.gov as #CA180015.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
H. Kantarjian, J. Cortes, D.-W. Kim, P. Dorlhiac-Llacer, R. Pasquini, J. DiPersio, M. C. Muller, J. P. Radich, H. J. Khoury, N. Khoroshko, et al.
Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up
Blood,
June 18, 2009;
113(25):
6322 - 6329.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N.V. Rajeshkumar, A. C. Tan, E. De Oliveira, C. Womack, H. Wombwell, S. Morgan, M. V. Warren, J. Walker, T. P. Green, A. Jimeno, et al.
Antitumor Effects and Biomarkers of Activity of AZD0530, a Src Inhibitor, in Pancreatic Cancer
Clin. Cancer Res.,
June 15, 2009;
15(12):
4138 - 4146.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Eley, F. R. Luo, S. Agrawal, A. Sanil, J. Manning, T. Li, A. Blackwood-Chirchir, and R. Bertz
Phase I Study of the Effect of Gastric Acid pH Modulators on the Bioavailability of Oral Dasatinib in Healthy Subjects
J. Clin. Pharmacol.,
June 1, 2009;
49(6):
700 - 709.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Fava, H. M. Kantarjian, E. Jabbour, S. O'Brien, N. Jain, M. B. Rios, G. Garcia-Manero, F. Ravandi, S. Verstovsek, G. Borthakur, et al.
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase
Blood,
May 21, 2009;
113(21):
5058 - 5063.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Fielding, J. M. Rowe, S. M. Richards, G. Buck, A. V. Moorman, I. J. Durrant, D. I. Marks, A. K. McMillan, M. R. Litzow, H. M. Lazarus, et al.
Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993
Blood,
May 7, 2009;
113(19):
4489 - 4496.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Tyler
Once-Daily Dasatinib for Treatment of Patients with Chronic Myeloid Leukemia
Ann. Pharmacother.,
May 1, 2009;
43(5):
920 - 927.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Lagas, R. A.B. van Waterschoot, V. A.C.J. van Tilburg, M. J. Hillebrand, N. Lankheet, H. Rosing, J. H. Beijnen, and A. H. Schinkel
Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment
Clin. Cancer Res.,
April 1, 2009;
15(7):
2344 - 2351.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-F. Wong
Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia
Journal of Oncology Pharmacy Practice,
March 1, 2009;
15(1):
17 - 27.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. M. O'Brien, D. A. Thomas, and S. Faderl
A La Carte Therapy of Specific Acute Lymphocytic Leukemia Subsets
ASCO Educational Book,
January 1, 2009;
2009(1):
365 - 370.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Rousselot, J.-M. Cayuela, C. Recher, T. Leguay, C. Salanoubat, F. Witz, M. Alexis, M. Janvier, M. Hunault, P. Agape, et al.
Dasatinib (Sprycel(R)) and Chemotherapy for First-Line Treatment in Elderly Patients with De Novo Philadelphia Positive ALL: Results of the First 22 Patients Included in the EWALL-Ph-01 Trial (on Behalf of the European Working Group on Adult ALL (EWALL))
Blood (ASH Annual Meeting Abstracts),
November 16, 2008;
112(11):
2920 - 2920.
[Abstract]
|
|
|
|
|
|
|
K. Porkka, P. Koskenvesa, T. Lundan, J. Rimpilainen, S. Mustjoki, R. Smykla, R. Wild, R. Luo, M. Arnan, B. Brethon, et al.
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia
Blood,
August 15, 2008;
112(4):
1005 - 1012.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. P. Shah, H. M. Kantarjian, D.-W. Kim, D. Rea, P. E. Dorlhiac-Llacer, J. H. Milone, J. Vela-Ojeda, R. T. Silver, H. J. Khoury, A. Charbonnier, et al.
Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia
J. Clin. Oncol.,
July 1, 2008;
26(19):
3204 - 3212.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. K. Hiwase, V. Saunders, D. Hewett, A. Frede, S. Zrim, P. Dang, L. Eadie, L. B. To, J. Melo, S. Kumar, et al.
Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications
Clin. Cancer Res.,
June 15, 2008;
14(12):
3881 - 3888.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. G. Harb, B. I. Chyla, and C. S. Huettner
Loss of Bcl-x in Ph+ B-ALL increases cellular proliferation and does not inhibit leukemogenesis
Blood,
April 1, 2008;
111(7):
3760 - 3769.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Wetzler
Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia: On Target to Improve Outcome
ASCO Educational Book,
January 1, 2008;
2008(1):
275 - 279.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
